Evidence map›Paper›PMID 21628661›Full record

SynthesisThe Journal of infectious diseases2011

A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs.

Holly Hagan, Enrique R Pouget, Don C Des Jarlais

Open access · greenAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The Journal of infectious diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 20 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed, 20 pooled it
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

152 citing papers in PubMed, 20 syntheses or guidelines pooled it, 318 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. High hepatitis C virus prevalence among drug users in Iran: systematic review and meta-analysis of epidemiological evidence (2001-2012).International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2015
    Pooled it
  16. Guideline
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Holly HaganNew York University College of Nursing, NY, USA. hh50@nyu.edu
Enrique R Pouget
Don C Des Jarlais
Mount Sinai Beth Israel · USNational Development and Research Institutes · USNew York University · US

Funding

Synthesis: HCV Epidemiology and Prevention in Drug UsersR01DA018609 · NIDA · NATIONAL DEVELOPMENT &RES INSTITUTES · PI HAGAN, HOLLY C. · 2004 to 2006
$1.3M
NIDA NIH HHS P30 DA121041NIDA NIH HHS R01 DA018609
6 · The paper itself

Abstract

introductionHigh rates of hepatitis C virus (HCV) transmission are found in samples of people who inject drugs (PWID) throughout the world. The objective of this paper was to meta-analyze the effects of risk-reduction interventions on HCV seroconversion and identify the most effective intervention types.

methodsWe performed a systematic review and meta-analysis of published and unpublished studies. Eligible studies reported on the association between participation in interventions intended to reduce unsafe drug injection and HCV seroconversion in samples of PWID.

resultsThe meta-analysis included 26 eligible studies of behavioral interventions, substance-use treatment, syringe access, syringe disinfection, and multicomponent interventions. Interventions using multiple combined strategies reduced risk of seroconversion by 75% (pooled relative risk, .25; 95% confidence interval, .07-.83). Effects of single-method interventions ranged from .6 to 1.6.

conclusionsInterventions using strategies that combined substance-use treatment and support for safe injection were most effective at reducing HCV seroconversion. Determining the effective dose and combination of interventions for specific subgroups of PWID is a research priority. However, our meta-analysis shows that HCV infection can be prevented in PWID.

Indexed as

Behavior TherapyCommunicable Disease ControlDisease Transmission, InfectiousHepatitis CHumansSubstance Abuse, IntravenousTreatment Outcome

Identifiers

PMID21628661
PMCPMC3105033
OpenAlexW2110957526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.